Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting. This clinical setting seems ideal for evaluation of the role of bevacizumab in delaying progression and prolonging survival.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: SCRI Development Innovations, LLC
• Collaborator: Genentech, Inc.
• Treatments: Bevacizumab; Camptothecin; Carboplatin; Irinotecan

Criteria

Inclusion Criteria:

• Histologically confirmed small cell lung cancer,extensive stage disease.

• Measurable or evaluable disease

• No previous chemotherapy

• Able to perform activities of daily living with minimal assistance

• Adequate hematological, live and kidney function

• Provide written informed consent

Exclusion Criteria:

• Limited stage disease

• PEG or G tubes

• Hemoptysis

• Abdominal fistula, perforation, or abscess within the previous 6 months

• Women who are pregnant or lactating

• Proteinuria

• Serious nonhealing wound, ulcer, or bone fracture

• Evidence of bleeding diathesis or coagulopathy

• Uncontrolled or serious cardiovascular disease

• Uncontrolled brain metastasis

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days; Fine needle aspiration within 7 days

• Patients requiring full-dose anticoagulation must be on a stable dosing schedule prior to enrollment